Neurogene Inc. (NGNE): EPS (Diluted)
-$4.24
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$4.24 | n/m | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | -$4.28 | n/c | 2026-03-24, From 2024-01-01 |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | -$1.04 | n/m | 2023-03-20, From 2022-01-01 |
| 2021-12-31 | -$1.10 | n/m | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | -$0.64 | n/a | 2022-03-01, From 2020-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Neurogene Inc. (NGNE) | 2025-12-31 | -$4.24 | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $3.72 | -51.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $3.46 | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$0.05 | n/m |
| Eli Lilly & Co (LLY) | 2025-12-31 | $22.95 | +96.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.36 | -3.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $11.03 | +90.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.06 | +165.0% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $7.28 | +8.0% |
Compare NGNE, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗